Cargando…
Budesonide for the Induction and Maintenance of Remission in Crohn’s Disease: Systematic Review and Meta-Analysis for the Cochrane Collaboration
BACKGROUND: Budesonide is an oral glucocorticoid designed for the treatment of inflammatory bowel disease (IBD) that may reduce systemic adverse events (AEs). This review examined the efficacy and safety of budesonide for the induction and maintenance of clinical remission in Crohn’s disease (CD). M...
Autores principales: | Kuenzig, M Ellen, Rezaie, Ali, Kaplan, Gilaad G, Otley, Anthony R, Steinhart, A Hillary, Griffiths, Anne Marie, Benchimol, Eric I, Seow, Cynthia H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328928/ https://www.ncbi.nlm.nih.gov/pubmed/30656288 http://dx.doi.org/10.1093/jcag/gwy018 |
Ejemplares similares
-
Surgery for Inflammatory Bowel Disease Has Unclear Impact on Female Fertility: A Cochrane Collaboration Systematic Review
por: Lee, Sangmin, et al.
Publicado: (2020) -
Vedolizumab for induction and maintenance of remission in Crohn's disease
por: Hui, Samuel, et al.
Publicado: (2023) -
Endospore forming bacteria may be associated with maintenance of surgically-induced remission in Crohn’s disease
por: Laffin, Michael R., et al.
Publicado: (2018) -
Patient preferences for maintenance therapy in Crohn’s disease: A discrete-choice experiment
por: Hazlewood, Glen S., et al.
Publicado: (2020) -
Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease
por: Zittan, Eran, et al.
Publicado: (2021)